Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (151-160 of 282) with videos related to

Pageof 29
Sort By:
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Arthritis and Rheumatism|January 13, 2011
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label studyJérémie Sellam, Houria Hendel-Chavez, Stéphanie Rouanet, et al.
Plos One|October 14, 2017
Sodium excretion is higher in patients with rheumatoid arthritis than in matched controlsSarah Marouen, Guilhem du Cailar, Rachel Audo, et al.
Arthritis and Rheumatism|December 1, 2011
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritisJérémie Sellam, Stéphanie Rouanet, Houria Hendel-Chavez, et al.
Arthritis Research & Therapy|January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Annals of the Rheumatic Diseases|August 9, 2012
Etanercept normalises left ventricular mass in patients with rheumatoid arthritisClaire Immediato Daïen, Pierre Fesler, Guilhem du Cailar, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialMark C Genovese, Roy Fleischmann, Bernard Combe, et al.
Joint Bone Spine|April 12, 2014
Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practiceAline Frazier-Mironer, Maxime Dougados, Xavier Mariette, et al.
RMD Open|July 23, 2024
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohortAnna Molto, Chris Serrand, Sandrine Alonso, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Pageof 29

Showing results (151-160 of 282) with videos related to

Sort By:
Pageof 29
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Arthritis and Rheumatism|January 13, 2011
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label studyJérémie Sellam, Houria Hendel-Chavez, Stéphanie Rouanet, et al.
Plos One|October 14, 2017
Sodium excretion is higher in patients with rheumatoid arthritis than in matched controlsSarah Marouen, Guilhem du Cailar, Rachel Audo, et al.
Arthritis and Rheumatism|December 1, 2011
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritisJérémie Sellam, Stéphanie Rouanet, Houria Hendel-Chavez, et al.
Arthritis Research & Therapy|January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Annals of the Rheumatic Diseases|August 9, 2012
Etanercept normalises left ventricular mass in patients with rheumatoid arthritisClaire Immediato Daïen, Pierre Fesler, Guilhem du Cailar, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialMark C Genovese, Roy Fleischmann, Bernard Combe, et al.
Joint Bone Spine|April 12, 2014
Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practiceAline Frazier-Mironer, Maxime Dougados, Xavier Mariette, et al.
RMD Open|July 23, 2024
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohortAnna Molto, Chris Serrand, Sandrine Alonso, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Pageof 29